La vendita allo scoperto per Emergent BioSolutions dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Emergent BioSolutions. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Emergent BioSolutions (NYSE:EBS) Azioni, Report sulle vendite allo scoperto

EMERGENT BIOSOLUTIONS INC

Emergent BioSolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Emergent BioSolutions Inc

EMPIRE BANCSHARES INC by Empire Bancshares Inc.

Empire Bancshares Inc

<h3>Gainers</h3>
<ul>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) shares increased by 17.4% to $9.32 during Wednesday's after-market session. The market value of their outstanding shares is at $2.8 billion. As per the press release, Q1 earnings came out today. </li>
<li>Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) stock increased by 15.38% to $0.45. The company's market cap stands at $30.1 million. As per the press release, Q1 earnings came out today. </li>
<li>Revolution Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) stock increased by 12.9% to $42.52. The company's market cap stands at $7.9 billion. The company's, Q1 earnings came out today. </li>
<li>GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) stock increased by 8.97% to $4.13. The market value of their outstanding shares is at $1.4 billion. As per the press release, Q1 earnings came out today. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) shares increased by 8.79% to $0.23. The company's market cap stands at $9.7 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock increased by 8.43% to $5.14. The company's market cap stands at $279.2 million. The company's, Q1 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 70.2% to $0.09 during Wednesday's after-market session. </li>
<li>electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) stock decreased by 14.08% to $5.85. The market value of their outstanding shares is at $42.0 million. The company's, Q1 earnings came out today. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock fell 13.98% to $0.01. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) stock declined by 13.47% to $5.91. The company's market cap stands at $105.7 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) stock decreased by 12.04% to $17.1. The company's market cap stands at $846.8 million. As per the news, the Q1 earnings report came out today. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) shares fell 10.18% to $0.66. The company's market cap stands at $2.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALVO

CARM

ECOR

GBIO

GDRX

LGMK

NCNA

RVMD

STAA

12 Health Care Stocks Moving In Wednesday's After-Market Session

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) affirms FY2025 sales outlook from $750.00 million-$850.00 million to $750.00 million-$850.00 million vs $819.33 million estimate.

News

Guidance

Emergent BioSolutions Affirms FY2025 Sales Guidance of $750.00M-$850.00M vs $819.33M Est

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.44 by 61.36 percent. This is a 20.34 percent increase over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $222.20 million which beat the analyst consensus estimate of $219.00 million by 1.46 percent. This is a 26.03 percent decrease over sales of $300.40 million the same period last year.

Earnings

Earnings Beats

Emergent BioSolutions Q1 Adj. EPS $0.71 Beats $0.44 Estimate, Sales $222.20M Beat $219.00M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $15 Price Target

Buybacks

Emergent BioSolutions Approves $50M Shares Buyback On Or Before March 27, 2026

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Emergent BioSolutions and provided 12-month price targets. The average target is $15.0, accompanied by a high estimate of $15.00 and a low estimate of $15.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1742562027_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Emergent BioSolutions among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Emergent BioSolutions. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Emergent BioSolutions compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Emergent BioSolutions's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Emergent BioSolutions's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EBS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Emergent BioSolutions analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Emergent BioSolutions Better</h2>
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
<h3>Emergent BioSolutions's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Emergent BioSolutions's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -29.86% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Emergent BioSolutions's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -16.53%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Emergent BioSolutions's ROE stands out, surpassing industry averages. With an impressive ROE of -6.32%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.18%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 1.37, Emergent BioSolutions faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts

Biotech

Contracts

General

Hikma Announces Health Canada Approval Of KLOXXADO Nasal Spray; To Be Marketed, Sold By Emergent BioSolutions Under 6-Year Commercial Agreement

Asset Sales

Emergent BioSolutions Finalizes Baltimore-Bayview Manufacturing Site Sale To Syngene International; Emergent Receive ~$36.5M

Emergent BioSolutions Secures ~ $27M In International Orders To Address Potential Threats Of Smallpox And Anthrax And Will Contribute To The Overall Supply Of MCM's To The International Market In 2025

Emergent BioSolutions Announces Agreement For Investment Into Swiss Rockets

Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
As part of the agreement, Emergent will retain the rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene. Emergent continues to operate a streamlined manufacturing network, including facilities in Lansing, Michigan and Winnipeg, Manitoba, Canada capable of serving strategic partners and supporting large-scale projects.

Emergent BioSolutions Announces Sale Of Baltimore-Bayview Manufacturing Site To Syngene International For $36.5M

U.S. stocks plunged Tuesday as President Donald Trump&#8216;s tariffs on key trade partners came into effect, prompting retaliatory measures and intensifying <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44110685/markets-see-hardly-a-flesh-wound-so-far-but-centurys-biggest-trade-war-looms-says-bob-elliott">global trade tensions.</a>
The Dow Jones Industrial Average fell 1.8%, extending Monday&#8217;s sharp decline of nearly 650 points and heading towards its worst performance of 2025. The S&amp;P 500 decreased by 1.7%, while the Nasdaq Composite dropped 1.9%, putting it<a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44108913/tariffs-trump-tumult-how-to-trade-this-volatility-vix-surge"> on course</a> to enter correction territory, defined as a 10% drop from its recent peak.&nbsp;
Read More: <a href="https://www.benzinga.com/news/earnings/25/03/44110273/trump-tariffs-will-raise-prices-within-days-target-ceo-says">Trump Tariffs Will Raise Prices &#8216;Within Days,&#8217; Target CEO Says</a>
<a href="https://www.benzinga.com/25/03/44102599/canadian-pm-justin-trudeau-retaliates-with-25-tariffs-on-us-goods-amid-escalating-trade-war">Affected countries</a> announced retaliatory measures, further dampening investor sentiment.
China announced retaliatory tariffs of up to 15% on certain U.S. products, including chicken, wheat, corn, and cotton. Canadian Prime Minister Justin Trudeau declared that Canada would impose a 25% tariff on U.S. goods. Mexican President Claudia Sheinbaum stated that Mexico would respond with tariffs and other measures, to be announced on Sunday.
The yield on the US 10-year Treasury note fell to 4.13% on Tuesday, its lowest level since October 2024. Markets are now pricing in three quarter-point rate cuts by the Federal Reserve in 2025, according to data from CME FedWatch. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) slipped 0.58%. 
Natural gas futures rose more than 8% on Tuesday, above $4.45/MMBtu, the highest since December 2022. Stockpiles remain below the five-year average due to earlier extreme cold in the U.S. while LNG export flows have reached record levels. The United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) ETF climbed 8.5%.&nbsp;
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continued Monday's decline to trade below the $84,000 mark, leading crypto markets lower. 
<h2 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,175.89</td>
<td>-0.99%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,772.73</td>
<td>-1.32%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,535.92</td>
<td>-1.52%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,064.42</td>
<td>-1.81%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 1.24% to $576.36. </li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 1.45% at $425.81.&nbsp;</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.8% to $493.08.&nbsp;</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) slid 1.1% to $205.00.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) was down 2.17% to $207.38.&nbsp;</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) was down 1.06% to $86.87.&nbsp;</li>
</ul>
<h2 class="wp-block-heading">Tuesday's Stock Movers:&nbsp;</h2>
Shares of Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>), bucked the market trend, surging 18% after the company reported&nbsp;better-than-expected <a href="https://www.benzinga.com/analyst-ratings/upgrades/25/03/44108947/okta-stock-is-surging-tuesday-heres-why">financial results</a> on Monday. 
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>)&nbsp;</li>
<li>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)&nbsp;</li>
<li>B. Riley Financial, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>)&nbsp;</li>
<li>Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>)&nbsp;</li>
<li>NuScale Power Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>)&nbsp;</li>
<li>GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>)&nbsp;</li>
<li>Curaleaf Hldgs Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>)&nbsp;</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>)&nbsp;</li>
<li>Emergent BioSolutions Inc.&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)&nbsp;</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)&nbsp;</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>)&nbsp;</li>
</ul>
Companies reporting after Tuesday's closing bell include:&nbsp;
<ul>
<li>ChargePoint Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>)</li>
<li>Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) </li>
<li>Rigel Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) </li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) </li>
<li>Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) </li>
<li>Sociedad Quimica y Minera S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) </li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) </li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) </li>
</ul>
Read Next:<a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">Markets Tank After Trump Confirms More Tariffs: Here&#8217;s What Wall Street Is Saying</a></li>
</ul>
Image: Shutterstock

Large Cap

Market Summary

Sector ETFs

Broad U.S. Equity ETFs

Global

ETFs

$BTC

ASTS

AVAV

CHPT

CRWD

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

DAVE

SPDR Dow Jones Industrial Average ETF Trust

GTLB

OKTA

RIGL

RILY

ROST

STEM

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday?

During the last three months, 4 analysts shared their evaluations of Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.0, along with a high estimate of $15.00 and a low estimate of $15.00. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1741096840_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Emergent BioSolutions. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Emergent BioSolutions. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Emergent BioSolutions compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Emergent BioSolutions's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Emergent BioSolutions's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EBS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Emergent BioSolutions analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Emergent BioSolutions Better</h2>
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
<h3>Emergent BioSolutions: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Emergent BioSolutions displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 7.5%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 40.45%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Emergent BioSolutions's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 25.66% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 7.68%, the company showcases effective utilization of assets.
Debt Management: Emergent BioSolutions's debt-to-equity ratio surpasses industry norms, standing at 1.3. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Emergent BioSolutions Stands With Analysts

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) sees FY2025 sales of $750.000 million-$850.000 million vs $1.13 billion analyst estimate.

Emergent BioSolutions Sees FY2025 Sales $750.000M-$850.000M vs $1.13B Est

WIIM

Emergent BioSolutions shares are trading lower after the company reported worse-than-expected Q4 revenue results.

Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.49) by 110.2 percent. This is a 106.49 percent increase over losses of $(0.77) per share from the same period last year. The company reported quarterly sales of $194.70 million which missed the analyst consensus estimate of $254.67 million by 23.55 percent. This is a 29.61 percent decrease over sales of $276.60 million the same period last year.

Earnings Misses

Emergent BioSolutions Q4 Adj $0.05 Beats $(0.49) Estimate, Sales $194.70M Miss $254.67M Estimate

Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%, down <a href="https://www.benzinga.com/general/market-summary/25/03/44081294/tariffs-weigh-on-us-manufacturing-february-prices-grow-at-fastest-pace-since-2022">from 50.9% in January.&nbsp;</a>
Overall demand weakened in February, new orders and employment contracted and production growth decelerated sharply. The impact of new tariffs drove prices higher at the fastest pace since June 2022,&nbsp; according to Trading Economics. Additional tariffs are set to go into effect on Tuesday, dampening investor sentiment.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/02/44015237/pending-home-sales-crash-to-record-low-jobless-claims-soar-wall-street-reacts">Pending Home Sales Crash To Record Low, Jobless Claims Soar: Wall Street Reacts</a>
The tech sector was Monday's worst performer, led lower by Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>). The SPDR Select Sector Technology Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) was down 0.63% and the tech-heavy Nasdaq 100 slipped 0.5%.&nbsp;
The yield on the 10-year US Treasury note fell to 4.2% on Monday, down 35bps in the last nine sessions. The iShares 20+ Year Treasury Bond ETF was down by 0.16%. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies were down after rallying on Sunday following President Trump's announcement of the creation of a strategic reserve that would include bitcoin, Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and other popular cryptos.&nbsp;
<h2 class="wp-block-heading">Monday's Performance In Major U.S. Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,775.16</td>
<td>-0.38%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,943.70</td>
<td>-0.19%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,734.63</td>
<td>-0.24%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,148.56</td>
<td>-0.67%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) slipped 0.15% to $593.29. </li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.16% at $437.68.&nbsp;</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.03% to $508.33. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.43% to $213.73.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) rose 0.16% to $216.30. </li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) fell 0.63% to $90.43. </li>
</ul>
<h2 class="wp-block-heading">Monday's Stock Movers: </h2>
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) climbed 3% after a Morgan Stanley analyst predicted a rebound in the beaten down stock. Tesla stock remains down <a href="https://www.benzinga.com/government/regulations/25/03/44071203/tesla-falls-nearly-23-destroying-354-billion-of-investor-wealth-in-2025-its-only-going-to-get-worse-says-top-investor">by more</a> than 20% over the past month. 
Stocks reacting to company earnings reports included: 
<ul>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>)&nbsp;</li>
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>)&nbsp;</li>
<li>Fortrea Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>)</li>
<li>Burford Capital Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>)&nbsp;</li>
<li>N-able, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>)&nbsp;</li>
<li>Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>)&nbsp;</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)</li>
<li>Ready Capital Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>)&nbsp;</li>
<li>Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>)&nbsp;</li>
</ul>
Companies reporting after Monday's closing bell include: 
<ul>
<li>B. Riley Financial, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>)&nbsp;</li>
<li>Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>)&nbsp;</li>
<li>NuScale Power Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>)&nbsp;</li>
<li>GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>)&nbsp;</li>
<li>Curaleaf Hldgs Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>)&nbsp;</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>)&nbsp;</li>
<li>Emergent BioSolutions Inc.&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)&nbsp;</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)&nbsp;</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>)&nbsp;</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/02/43977811/mortgage-rates-drop-to-lowest-levels-since-december-but-housing-market-remains-largely-stuck">Mortgage Rates Drop To Lowest Levels Since December, But Housing Market Remains &#8216;Largely Stuck&#8217;&nbsp;</a></li>
</ul>
Image: Shutterstock

Equities

Bonds

Markets

Tech

$ETH

AMZN

AVGO

BHVN

FTRE

IBRX

NABL

NOVA

SAVA

TSLA

Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?

Press Releases

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Health Care

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Emergent BioSolutions Announces Stock Repurchase Program

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Comments

Emergent BioSolutions

Vendite allo scoperto

Emergent BioSolutions (NYSE:EBS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO